359 related articles for article (PubMed ID: 27104980)
41. Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo.
Block C; Janknecht R; Herrmann C; Nassar N; Wittinghofer A
Nat Struct Biol; 1996 Mar; 3(3):244-51. PubMed ID: 8605626
[TBL] [Abstract][Full Text] [Related]
42. Interactions between Ras proteins and their effectors.
McCormick F; Wittinghofer A
Curr Opin Biotechnol; 1996 Aug; 7(4):449-56. PubMed ID: 8768906
[No Abstract] [Full Text] [Related]
43. Ras-effector interactions, the problem of specificity.
Wittinghofer A; Herrmann C
FEBS Lett; 1995 Aug; 369(1):52-6. PubMed ID: 7641884
[TBL] [Abstract][Full Text] [Related]
44. Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair.
Malacrida A; Cavaletti G; Miloso M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008638
[TBL] [Abstract][Full Text] [Related]
45. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.
Martinez NG; Thieker DF; Carey LM; Rasquinha JA; Kistler SK; Kuhlman BA; Campbell SL
J Mol Biol; 2021 Apr; 433(8):166838. PubMed ID: 33539876
[TBL] [Abstract][Full Text] [Related]
46. Solution structure of the Ras-binding domain of c-Raf-1 and identification of its Ras interaction surface.
Emerson SD; Madison VS; Palermo RE; Waugh DS; Scheffler JE; Tsao KL; Kiefer SE; Liu SP; Fry DC
Biochemistry; 1995 May; 34(21):6911-8. PubMed ID: 7766599
[TBL] [Abstract][Full Text] [Related]
47. Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation.
Kimoto M; Shirouzu M; Mizutani S; Koide H; Kaziro Y; Hirao I; Yokoyama S
Eur J Biochem; 2002 Jan; 269(2):697-704. PubMed ID: 11856330
[TBL] [Abstract][Full Text] [Related]
48. RNA aptamers that specifically bind to the Ras-binding domain of Raf-1.
Kimoto M; Sakamoto K; Shirouzu M; Hirao I; Yokoyama S
FEBS Lett; 1998 Dec; 441(2):322-6. PubMed ID: 9883908
[TBL] [Abstract][Full Text] [Related]
49. KSR as a therapeutic target for Ras-dependent cancers.
Neilsen BK; Frodyma DE; Lewis RE; Fisher KW
Expert Opin Ther Targets; 2017 May; 21(5):499-509. PubMed ID: 28333549
[TBL] [Abstract][Full Text] [Related]
50. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.
Baker SJ; Cosenza SC; Athuluri-Divakar S; Reddy MVR; Vasquez-Del Carpio R; Jain R; Aggarwal AK; Reddy EP
Mol Cell; 2020 Jul; 79(1):180-190.e4. PubMed ID: 32619468
[TBL] [Abstract][Full Text] [Related]
51. Structural and mechanistic insights into ras association domains of phospholipase C epsilon.
Bunney TD; Harris R; Gandarillas NL; Josephs MB; Roe SM; Sorli SC; Paterson HF; Rodrigues-Lima F; Esposito D; Ponting CP; Gierschik P; Pearl LH; Driscoll PC; Katan M
Mol Cell; 2006 Feb; 21(4):495-507. PubMed ID: 16483931
[TBL] [Abstract][Full Text] [Related]
52. B-Raf autoinhibition in the presence and absence of 14-3-3.
Zhang M; Jang H; Li Z; Sacks DB; Nussinov R
Structure; 2021 Jul; 29(7):768-777.e2. PubMed ID: 33711246
[TBL] [Abstract][Full Text] [Related]
53. Raf-like Ras/Rap-binding domains in RGS12- and still-life-like signalling proteins.
Ponting CP
J Mol Med (Berl); 1999 Oct; 77(10):695-8. PubMed ID: 10606204
[TBL] [Abstract][Full Text] [Related]
54. Structural and thermodynamic characterization of Nore1-SARAH: a small, helical module important in signal transduction networks.
Makbul C; Constantinescu Aruxandei D; Hofmann E; Schwarz D; Wolf E; Herrmann C
Biochemistry; 2013 Feb; 52(6):1045-54. PubMed ID: 23331050
[TBL] [Abstract][Full Text] [Related]
55. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
Wang Y; Kaiser CE; Frett B; Li HY
J Med Chem; 2013 Jul; 56(13):5219-30. PubMed ID: 23566315
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
57. Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP.
Nelson ML; Kang HS; Lee GM; Blaszczak AG; Lau DK; McIntosh LP; Graves BJ
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10026-31. PubMed ID: 20534573
[TBL] [Abstract][Full Text] [Related]
58. Integrated RAS signaling defined by parallel NMR detection of effectors and regulators.
Smith MJ; Ikura M
Nat Chem Biol; 2014 Mar; 10(3):223-30. PubMed ID: 24441586
[TBL] [Abstract][Full Text] [Related]
59. Structure of the Ras-binding domain of RalGEF and implications for Ras binding and signalling.
Geyer M; Herrmann C; Wohlgemuth S; Wittinghofer A; Kalbitzer HR
Nat Struct Biol; 1997 Sep; 4(9):694-9. PubMed ID: 9302994
[TBL] [Abstract][Full Text] [Related]
60. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
